Inspired by the successful television series, the UCL School of Pharmacy has organised this clever and well-attended event where UCL scientists presented their small molecule therapeutics idea to a panel of seasoned pharma experts and investors, in front of a public of scientists and company representatives. We couldn’t resist the temptation to pitch our Virology Research Services, and although VRS is not quite a small molecule, it was clearly exciting enough to win the third prize from the public! Thank you!
Recents Posts
Influenza and Diabetes: Why Metabolic Health Matters in Viral Infection
Influenza is usually described as a respiratory virus, but its impact does not stop at the airways. For many people, flu is a short-lived illness of fever, cough, fatigue, and muscle aches. For others, particularly those with underlying metabolic disease, it can...
Current and Future Antiviral Research
A virus mutates, an antiviral loses potency, and a new outbreak finds us one step behind. This cycle has defined antiviral medicine for decades. Now, a convergence of broad-spectrum drug design, host-targeted therapies, AI-driven discovery, nanotechnology, and CRISPR...
VRS Successfully Maintains ISO 9001 Certification
Virology Research Services is pleased to announce that we have successfully maintained our ISO 9001:2015 certification following our latest annual audit. This recertification confirms the continued strength and effectiveness of our Quality Management System (QMS). In...
When it comes to viruses, we know our stuff!
Subscribe


